Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a specific transaction involving the acquisition of 101 Ordinary Shares at a price of £16.34 per share.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction: the acquisition of shares by CEO Sir Andrew Witty following the re-investment of dividends paid on July 14, 2016, within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is strictly a regulatory disclosure of an insider transaction executed on the London Stock Exchange on July 15, 2016.
Investor Verification Points
- Verify the transaction date of July 15, 2016, and the execution price of £16.34.
- Confirm the nature of the transaction as a dividend re-investment within an ISA.
- Note that this filing does not contain financial performance data for the period.